09.26.13
Catalent Pharma Solutions has expanded its OptiMeltT Hot Melt Extrusion (HME) capabilities in Somerset, NJ. The OptiMelt technology is designed to help overcome bioavailability challenges and create optimal delivery profiles and better dose forms. Catalent added a commercial scale extruder, supplementing the development scale equipment on site, and expanded its offerings to include lab, development, and commercial scale hot melt extrusion co-located with final dose form technologies across its Somerset and Schorndorf, Germany facilities.
The integrated OptiMelt platform combines development and scale-up of HME technology with oral controlled release formulation and final dose form development, including tablets, capsules and granules. According to the company, results from more than 10 feasibility studies for customers using OptiMelt technology have demonstrated its bioavailability enhancing capabilities. These programs were conducted across various therapeutic areas and stages of development, with several advancing to further development scale.
Barry Littlejohns, president of Catalent's new Advanced Delivery Technologies business, said, "Our OptiMelt HME platform has continued to strengthen in the last year as development partners have recognized the benefits of our technologies. Our added commercial HME capacity will support customers' projects as they transition to later phase clinical development and commercial supply, and also new customers desiring commercial scale direct tech transfers to our Somerset, NJ facility."
The integrated OptiMelt platform combines development and scale-up of HME technology with oral controlled release formulation and final dose form development, including tablets, capsules and granules. According to the company, results from more than 10 feasibility studies for customers using OptiMelt technology have demonstrated its bioavailability enhancing capabilities. These programs were conducted across various therapeutic areas and stages of development, with several advancing to further development scale.
Barry Littlejohns, president of Catalent's new Advanced Delivery Technologies business, said, "Our OptiMelt HME platform has continued to strengthen in the last year as development partners have recognized the benefits of our technologies. Our added commercial HME capacity will support customers' projects as they transition to later phase clinical development and commercial supply, and also new customers desiring commercial scale direct tech transfers to our Somerset, NJ facility."